{"id":"NCT02656069","sponsor":"Xeris Pharmaceuticals","briefTitle":"Safety and Efficacy of G-Pen Compared to Lilly Glucagon for Hypoglycemia Rescue in Adult Type 1 Diabetics","officialTitle":"G-Pen (Glucagon Injection) Compared to Lilly Glucagon (Glucagon for Injection [RDNA Origin]) for Induced Hypoglycemia Rescue in Adult Patients With T1DM: A Phase 3, Multi-center, Randomized, Blinded, 2-Way Crossover Study to Evaluate Efficacy and Safety","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2017-03-15","primaryCompletion":"2017-08-14","completion":"2017-09-25","firstPosted":"2016-01-14","resultsPosted":"2018-09-28","lastUpdate":"2018-10-30"},"enrollment":80,"design":{"allocation":"RANDOMIZED","model":"CROSSOVER","masking":"TRIPLE","primaryPurpose":"TREATMENT"},"conditions":["Hypoglycemia","Diabetes Mellitus, Type 1"],"interventions":[{"type":"DRUG","name":"G-Pen (glucagon injection)","otherNames":["glucagon"]},{"type":"DRUG","name":"Lilly Glucagon (glucagon injection [rDNA origin])","otherNames":["glucagon"]}],"arms":[{"label":"G-Pen first, then Lilly Glucagon","type":"OTHER"},{"label":"Lilly Glucagon first, then G-Pen","type":"OTHER"}],"summary":"This is a blinded, randomized crossover study to compare the safety and efficacy of G-Pen (glucagon injection) to Lilly Glucagon (glucagon for injection \\[rDNA origin\\]) for hypoglycemia rescue of adult patients with type 1 diabetes.","primaryOutcome":{"measure":"Hypoglycemia Rescue: Intent-to-Treat Population","timeFrame":"At 30 minutes following administration of study drug","effectByArm":[{"arm":"G-Pen","deltaMin":74,"sd":null},{"arm":"Lilly Glucagon","deltaMin":79,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":22},"locations":{"siteCount":7,"countries":["United States","Canada"]},"refs":{"pmids":["34620618"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":78},"commonTop":["Nausea","Vomiting","Headache"]}}